# US 2021/0009507 A1 · Synthesis of (2S,3R,4R)-4,5-Dihydroxyisoleucine and Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0009507 A1
- Document ID: US20210009507A1
- Status: Published application
- Kind: A1
- Application number: 17/042,323
- Filed: 2019-03-29
- Published: 2021-01-14
- Earliest claimed: 2018-03-29
- Assignees: Heidelberg Pharma Research GmbH; Corden Pharma International GmbH
- Applicants: Heidelberg Pharma Research GmbH; Corden Pharma International GmbH
- Inventors: Caroline Knittel; Mary-Ann Siegert; Roderich Süssmuth; Christoph Wink; Gerhard Jas
- Web page: https://patentgrep.com/patent/US20210009507A1

## CPC

- C07C 227/16: by reactions not involving the amino or carboxyl groups
- C07C 231/12: by reactions not involving the formation of carboxamide groups
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- B01J 21/063: {Titanium; Oxides or hydroxides thereof}
- C07C 233/47: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 269/04: from amines with formation of carbamate groups
- C07C 269/06: by reactions not involving the formation of carbamate groups
- C07D 301/03: by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
- C07D 303/40: by ester radicals
- C07D 317/20: Free hydroxyl or mercaptan
- C07D 317/72: spiro-condensed with carbocyclic rings
- C07D 319/20: with substituents attached to the hetero ring
- C07D 493/10: Spiro-condensed systems
- C07D 493/20: Spiro-condensed systems
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C12P 13/06: Alanine; Leucine; Isoleucine; Serine; Homoserine
- C07B 2200/07: Optical isomers
- C07C 229/30: the carbon skeleton being acyclic and unsaturated
- C07C 2601/02: with a three-membered ring
- C07C 2603/18: Fluorenes; Hydrogenated fluorenes
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The invention relates to a method for the preparation of a 4,5-dihydroxyisoleucine derivative comprising the steps of asymmetric Claisen rearrangement of a Z-aminocrotyl-glycin ester and subsequent kinetic resolution of the product diastereomer mix by acylase, and subsequent Sharpless dihydroxylation of the resulting 2-amino-3-methylpent-4-enoic acid derivative.

## Claims

### Claim 1

A method for the preparation of (2S,3S)-2-aminopent-4-enoic acid (30),
wherein said method comprises
a) the Claisen rearrangement step of reacting a Z-crotyl-glycin ester derivative 200
wherein R2A is an amino protecting group stable under conditions favourable to Claisen rearrangement,
in the presence of a chiral ligand to yield 2-aminopent-4-enoic acid derivative (300)
and
b) an enzymatic resolution step, wherein 2-aminopent-4-enoic acid derivative (310)
is converted to yield (2S,3S)-2-aminopent-4-enoic acid (30).

### Claim 2 (depends on 1)

The method of claim 1, wherein said chiral ligand is selected from ephedrin, valinol, cinchonidine, quinidine and cinchonine, particularly wherein the chiral ligand is quinidine, particularly wherein said chiral ligand is present in 2 to 3 molar equivalents in relation to compound 200.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Claisen rearrangement step proceeds in the presence of a strong non-nucleophilic base soluble in non-polar organic solvents, particularly a lithium or potassium alkylamide or lithium or potassium silylalkylamide, more particularly a base selected from LDA, LiTMP and LiHMDS, even more particularly in the presence of LiHMDS.

### Claim 4 (depends on 1)

The method of claim 1, wherein R2A and/or R2B is/are CHxF3-x(CHyF2-y)nCO— wherein n is 0 or 1, x is selected from 0, 1, 2 and 3 and y is selected from 0, 1 and 2, particularly R2A and/or R2B is/are selected from CF3CO—, CHF2CO—, CH2FCO—, CF3CO and CF3CF2CO.

### Claim 5 (depends on 1)

The method of claim 1, wherein the Claisen rearrangement step proceeds in the presence of LiHMDS and R2A is CF3CO—.

### Claim 6 (depends on 1)

The method of claim 1, wherein R2A is the same as R2B and the enzymatic resolution step is performed directly after the Claisen rearrangement step.

### Claim 7 (depends on 1)

A method for the preparation of a 2-amino-3-methylpent-4-enoic acid derivative from a crotyl glycinester derivative (200)
said method comprising the method according to claim 1 and further comprising:
a) a step of introducing an amino group protecting moiety R2C to the (2S,3S)-2-aminopent-4-enoic acid (30) or to a derivative of (30), thereby modifying the amino moiety by a protecting group moiety to yield (320) or—if step b) was performed before this step a)—to yield (330),
and/or
b) a step of introducing a carboxylic acid group protecting moiety R1C to the (2S,3S)-2-aminopent-4-enoic acid (30) or the derivative (320) obtained in step a), thereby modifying the carboxylic acid moiety modified by a protecting group moiety to yield (350) or (330).

### Claim 8 (depends on 1)

A method for the preparation of a (2S,3R,4R)-4,5-dihydroxyisoleucine derivative (400)
wherein:
R1 is H or a carboxylic acid moiety protecting group,
R2 is H or an amino moiety protecting group and
R3 and R4 are independently from another selected from H and a hydroxyl moiety protecting group, or both R3 and R4 are one single vicinal diol protecting group moiety, from a crotyl glycinester derivative (200), wherein said method comprises the method according to claim 1, and further comprises
a) a Sharpless dihydroxylation step, wherein 2-amino-3-methylpent-4-enoic acid derivative (330)
is reacted in the presence of Os(VIII) complexed by a chiral ligand, particularly by hydroquinidine 1,4-phthalazinediyl diether, to the 2-amino-3-methyl-4,5-dihydroxypentanoic acid derivative (430)
or
b) a Sharpless epoxidation step, wherein 2-amino-3-methylpent-4-enoic acid derivative (330)
is reacted in the presence of a chiral ligand and a catalyst comprising titanium isopropoxide to a (2S,3S,4R)-2-amino-3-methyl-4,5-epoxy-pentanoic acid derivative (360),
and
and subsequent enzymatic conversion catalysed by an epoxide hydrolase into 2-amino-3-methyl-4,5-dihydroxypentanoic acid derivative (430),
and wherein optionally, subsequent to step a) or b),
any amino group protecting moiety R2C and/or carboxylic acid group protecting moiety R1C is selectively removed from (430) to yield the free (2S,3R,4R)-4,5-dihydroxyisoleucine, or (430) is reacted with a vicinal diol protecting group, particularly to yield a compound selected from
wherein R1C and R2C have the same meaning as defined above and R5 and R5′ are independently selected from H and CH3.

### Claim 9 (depends on 1)

A method for the preparation of a (2S,3R)-5-hydroxyisoleucine derivative (410) from a crotyl glycinester derivative (200), wherein said method comprises the method according to claim 1, and further comprises a Sharpless epoxidation step, wherein 2-amino-3-methylpent-4-enoic acid derivative (330) is reacted in the presence of a chiral ligand and a catalyst comprising titanium isopropoxide to a (2S,3S,4R)-2-amino-3-methyl-4,5-epoxy-pentanoic acid derivative (360), which is subsequently reacted in the presence of a reducing agent to a 2-amino-3-methyl-5-hydroxypentanoic acid derivative (410),
with R1C and R2C having the same meaning as defined above.

### Claim 10 (depends on 1)

A method for the preparation of a (2S,3R)-4-hydroxyisoleucine derivative (440) from a crotyl glycinester derivative (200), wherein said method comprises the method according to claim 1, and further comprises a Sharpless epoxidation step, wherein 2-amino-3-methylpent-4-enoic acid derivative (330) is reacted in the presence of a chiral ligand and a catalyst comprising titanium isopropoxide to a (2S,3S,4R)-2-amino-3-methyl-4,5-epoxy-pentanoic acid derivative (360), which is subsequently reacted in the presence of a reducing agent to a 2-amino-3-methyl-4-hydroxypentanoic acid derivative (440),
with R1C and R2C having the same meaning as defined above.

### Claim 11 (depends on 7)

The method according to claim 7, wherein
R1C is a carboxylic acid moiety protecting group cleavable under acidic conditions,
particularly R1 is —C(RXRYRZ) with RX, RY and RZ independently selected from C1 to C4 alkyl, C3 to C6 cycloalkyl or substituted or unsubstituted aryl,
more particularly R1 is —C(RXRYRZ) wherein RX, RY and RZ are independently selected from methyl, cyclopropyl, alkyl cyclopropyl, phenyl, (p-) C6H4X with X being selected from Cl, NO2, and OCH3, or R1 is selected from 2,4-dimethoxybenzyl, 2-phenylisopropyl and 2-3,5-dimethoxyphenylisopropyl, even more particularly R1 is selected from tert-butyl (—C(CH3)3), CH2(cyclopropyl), CH(CH3)(cyclopropyl), C(CH3)2(cyclopropyl), CH(cyclopropyl)2, C(CH3)(cyclopropyl)2, and C(cyclopropyl)3
and/or
R2 is fluorenylmethyloxycarbonyl Fmoc)
and/or
R3 and R4 are independently from another selected from OCH3, X—C6H4 with X=o/m/p—halogen, OCH3, NO2, or R3 and R4 together are cyclopentyl or cyclohexyl (ketal of cyclopentanone/cyclohexanone), or
R3 and R4 together are 2,2,3,3-dimethoxy-butane or 1,2-dimethoxy-cyclohexane, or 3,3′,4,4′-tetrahydro-6,′6′-bi-2H-pyrane or a 4a,9a-dihydro-,(4aS,9aS)-9H-xanthen-9-one, or
R3 and R4 together are SiR′3R′4 or SiR′3R′4 0 SiR′3R′4 wherein each R′3 and R′4 is independently selected from C1 to C4 alkyl, C3 to C6 cycloalkyl or substituted or unsubstituted aryl, particularly each R′3 and R′4 is independently selected from CH3, i-C3H7, tert. C4H9 and phenyl,

### Claim 12 (depends on 8)

The method according to claim 8, wherein
a. R1 is H or tert-butyl, and/or
b. R2 is fluorenylmethyloxycarbonyl (Fmoc) or H and/or
c. R3 and/or R4 is selected from p-methoxy benzylidene, acetonide, acetate and trialkylsilyl, particularly trimethylsilyl, tert.-butyldimethylsilyl, tert.-butyldiphenylsilyl, triisopropylsilyl
d. R2 is Fmoc and R3 and R4 together are a benzyl or a substituted phenylmethyl (e.g. p-methoxy benzylidene), a dialkyl-substituted silyl group or a tetrasubstituted siloxane moiety.

### Claim 13

An intermediate in a synthesis of (2S,3S)-2-aminopent-4-enoic acid (30) or a derivative thereof, selected from:
a. [(Z)-but-2-enyl] 2-[(2,2,2-trifluoroacetyl)amino]acetate,
b. [(Z)-but-2-enyl] 2-[(2,2-difluoroacetyl)amino]acetate,
c. [(Z)-but-2-enyl] 2-[(2-fluoroacetyl)amino]acetate,
d. [(Z)-but-2-enyl] 2-(2,2,3,3,3-pentafluoropropanoylamino)acetate

### Claim 14 (depends on 1)

A derivative of compound (360)
prepared according to claim 1 with
R1C is a carboxylic acid moiety protecting group cleavable under acidic conditions,
particularly R1 is —C(RXRYRZ) with RX, RY and RZ independently selected from C1 to C4 alkyl, C3 to C6 cycloalkyl or substituted or unsubstituted aryl, more particularly R1 is —C(RXRYRZ) wherein RX, RY and RZ are independently selected from methyl, cyclopropyl, alkyl cyclopropyl, phenyl, (p-) C6H4X with X being selected from Cl, NO2, and OCH3, or R1 is selected from 2,4-dimethoxybenzyl, 2-phenylisopropyl and 2-3,5-dimethoxyphenylisopropyl, even more particularly R1 is selected from tert-butyl (—C(CH3)3), CH2(cyclopropyl), CH(CH3)(cyclopropyl), C(CH3)2(cyclopropyl), CH(cyclopropyl)2, C(CH3)(cyclopropyl)2, and C(cyclopropyl)3
and/or
R2 is fluorenylmethyloxycarbonyl Fmoc)

### Claim 15

A derivative of (2S,3R)-2-amino-3-methyl-4,5-dihydroxypentanoic acid (430) selected from
a. (2S,3R)-3-[(2R)-1,4-dioxaspiro[4.5]decan-2-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
b. (2S,3R)-3-[(2R)-6,9-dioxaspiro[4.4]nonan-2-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
c. (2S,3R)-3-[(2R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
d. (2S,3R)-3-[(2R)-4a,8a-dimethoxy-2,3,5,6,7,8-octahydrobenzo[b][1,4]dioxin-3-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
e. (2S,3R)-2-(fluorenylmethyloxycarbonylamino)-3-[(14R)-1,12,13,16-tetraoxadispiro[5.0.5.4]hexadecan-14-yl]butanoic acid;
f. (2S,3R)-3-[(4R)-2′,7′-dimethylspiro[1,3-dioxolane-2,9′-xanthene]-4-yl]-2-(fluorenylmethyloxycarbonylamino)butanoic acid;
g. (2S,3R)-3-[(4R)-spiro[1,3-dioxolane-2,9′-xanthene]-4-yl]-2-(fluorenylmethyloxycarbonylamino)butanoic acid;
h. (2S,3R)-3-[(4R)-2,2-diethyl-1,3-dioxolan-4-yl]-2-(fluorenylmethyloxycarbonylamino)butanoic acid
i. (2S,3R,4R)-3-methyl-4,5 bis(trimethylsilyl)oxy 2-(fluorenylmethyloxycarbonylamino)butanoic acid
j. (2S,3R,4R)-3-methyl-4,5 [(1,1-dimethylethyl)dimethylsilyl]oxy 2-(fluorenylmethyloxycarbonylamino)butanoic acid
k. (2S,3R)-3-[2,2,4,4,-tetramethyl-1,3,5-trioxa-2,4-disiloxylheptane-2yl-] 2-(fluorenylmethyloxycarbonylamino)butanoic acid
l. (2S,3R)-3-[2,2,4,4,-tetrakis (1-methylethyl)-1,3,5-trioxa-2,4-disiloxylheptane-2yl-] 2-(fluorenylmethyloxycarbonylamino)butanoic acid

### Claim 16 (depends on 15)

The tert.butylester, the cyclopropylmethyl or the dicyclopropylmethyl of any one of compounds of claim 15.
